Ernexa Therapeutics Inc. (ERNA) — SEC Financial Statements & Analysis

Ernexa Therapeutics Inc. (ERNA) is a pharmaceutical preparations company, incorporated in DE. Ernexa Therapeutics Inc. trades on Nasdaq as: ERNA, ERNAW. Ernexa Therapeutics Inc. (ERNA)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-06. Based on that filing, Ernexa Therapeutics Inc. carries a market cap of $7.87M, a P/E ratio of -0.64x, a P/B ratio of 2.46x, a P/S ratio of 9048.60x, an enterprise value of $2.84M, and an EV/EBITDA multiple of -0.21x. On profitability, it posts a gross margin of 83.51%, an operating margin of -992100.00%, a net margin of -1833200.00%, a Return on Equity (ROE) of -321.35%, a Return on Assets (ROA) of -176.73%, and a Return on Invested Capital (ROIC) of -3722.83%. Per share, it reports EPS of $-10.38, diluted EPS of $-10.38, free cash flow per share of $-7.50, and a dividend per share of $0.00. Over the trailing year, it posted revenue growth of -100.00% year-over-year, net income growth of -71.89% year-over-year, and EPS growth of -95.08% year-over-year. On the balance sheet, it maintains a current ratio of 2.01x, a quick ratio of 1.74x, working capital of $2.96M, a debt-to-equity ratio of 0.97x, a debt ratio of 0.49, an interest coverage ratio of -71.41x, free cash flow of $-8.88M (TTM), and net debt of $-5.03M. Figures sourced from SEC EDGAR.

Market Cap

$7.87M

P/E TTM

-0.64x

EPS TTM

$-10.38

P/B TTM

2.46x

ROE TTM

-321.35%

ROA TTM

-176.73%

Debt To Equity

0.97x

Free Cash Flow TTM

$-8.88M

Net Revenue TTM Growth 1Y

-100.00%

Data as of 2026-06-30 · Source: SEC EDGAR